Christoph H. Westphal

Co-Founder & General Partner at Longwood Fund Management LLC

Christoph H. Westphal

Christoph H. Westphal

Co-Founder & General Partner at Longwood Fund Management LLC

Overview
Career Highlights

GSK Equity Investments Ltd
Salarius Pharmaceuticals, Inc.
TScan Therapeutics, Inc.

RelSci Relationships

2598

Number of Boards

21

Birthday

1968

Age

53

Number of Awards

1

Relationships
RelSci Relationships are individuals Christoph H. Westphal likely has professional access to. A relationship does not necessarily indicate a personal connection.

Partner at RA Capital Management LP /Private equity

Relationship likelihood: Strong

Managing Director at General Atlantic Service Co. LP

Relationship likelihood: Strong

Professor at Harvard University

Relationship likelihood: Strong

Co-Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Professor at The Rockefeller University

Relationship likelihood: Strong

Former Chief Financial Officer & Executive Vice President at Ortho-Clinical Diagnostics, Inc.

Relationship likelihood: Strong

Senior Advisor at L.E.K. Consulting LLC

Relationship likelihood: Strong

Chief Executive Officer at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Concert Pharmaceuticals, Inc.

Relationship likelihood: Strong

General Partner at Advanced Technology Ventures

Relationship likelihood: Strong

Paths to Christoph H. Westphal
Potential Connections via
Relationship Science
You
Christoph H. Westphal
Co-Founder & General Partner at Longwood Fund Management LLC
Education
MD

Harvard Medical School (HMS) is the graduate medical school of Harvard University. It is located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts.The school was founded by John Warren on September 19, 1782, with Benjamin Waterhouse, and Aaron Dexter.

BA, Cumma cum laude, Phi Beta Kappa

Columbia University is one of the world's most important centers of research and at the same time a distinctive and distinguished learning environment for undergraduates and graduate students in many scholarly and professional fields. The University recognizes the importance of its location in New York City and seeks to link its research and teaching to the vast resources of a great metropolis. It seeks to attract a diverse and international faculty and student body, to support research and teaching on global issues, and to create academic relationships with many countries and regions. It expects all areas of the university to advance knowledge and learning at the highest level and to convey the products of its efforts to the world.

Ph.D Genetics

The oldest corporation in the Western Hemisphere is the Harvard Corporation, known formally as the President and Fellows of Harvard College. It is the smaller of Harvard’s two governing boards; the other is the Board of Overseers. Following are the members of the Harvard Corporation.

Memberships
Career History
Managing Member
2015 - Current
Co-Founder & General Partner
2010 - Current

Longwood Fund Management invests in companies located in the US. The firm targets companies operating in the fields healthcare and science companies. They provides financing for early stage capital requirements.

Manager
Current
Boards & Committees
Vice Chairman
2002 - Prior

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Director
Prior

Hydra Biosciences, Inc. develops pharmaceutical products. It is focused in major therapeutic areas, which include pain, inflammation, renal, anxiety, and pulmonary diseases. The company was founded by Laurie Bartlett Keating, Dean Y. Li, David E. Clapham, and Mark T. Keating in 2001 and is headquartered in Belmont, MA.

Member, Board of Directors
Prior

Nanosys, Inc. develops and manufactures inorganic nanostructures and other related products. It offers Ultra HD television. The company was founded by Paul A. Alivisatos, Stephen Empedocles, Peidong Yang, Robert M. Metcalfe, Jim Heath, Paul McEuen, Christoph H. Westphal, Moungi Bawendi, Lawrence A. Bock, Calvin Y. H. Chow, Chunming Niu, Karen Vergura, Hongkun Park, George Pontis and Charles M. Lieber in 2001 and is headquartered in Milpitas, CA.

Transactions
Details Hidden

Flex Pharma, Inc. raised money in a private placement transaction

Details Hidden

Verastem, Inc. raised money in a private placement transaction

Details Hidden

Verastem, Inc. raised money in a private placement transaction

Investments
Details Hidden

Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas.Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases.Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass.Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA.

Details Hidden

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Details Hidden

Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA.

Awards & Honors
Fortune Magazine - 40 under 40
Events
Speaker
New York City, NY
2013 UBS Global Healthcare Conference

Speaker
Sydney, QL, Australia
2010 Forbes Global CEO Conference

The Forbes Global CEO Conference 2010 took place in Sydney on September 28th to the 29th and gathered under one roof some 400 of the world's most influential captains of industry and thought-leaders to share insights on the best strategies to navigate the post-crisis economic landscape and seize new opportunities in volatile times. Hosted by the Australian Government and the New South Wales Government, it held the theme of "Full Sail Ahead", which likens today's business leader to a master mariner, whose challenge is to outwit the forces of uncertain economic conditions and whose determination is to capture new growth prospects through the power of innovation to create a prosperous and sustainable future.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Christoph H. Westphal. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Christoph H. Westphal's profile does not indicate a business or promotional relationship of any kind between RelSci and Christoph H. Westphal.